Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity

Pérez-Gómez JM., Montero-Hidalgo AJ., Fuentes-Fayos AC., Sarmento-Cabral A., Guzmán-Ruiz R., Malagón MM.

Clinical Trial on Systemic / IV, published in Rev Endocr Metab Disord (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Rev Endocr Metab Disord (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37819510
PMCID
PMC10697898
DOI
10.1007/s11154-023-09838-w
Citations
17

Abstract (original English)

Obesity is a weight-related disorder characterized by excessive adipose tissue growth and dysfunction which leads to the onset of a systemic chronic low-grade inflammatory state. Likewise, inflammation is considered a classic cancer hallmark affecting several steps of carcinogenesis and tumor progression. In this regard, novel molecular complexes termed inflammasomes have been identified which are able to react to a wide spectrum of insults, impacting several metabolic-related disorders, but their contribution to cancer biology remains unclear. In this context, prostate cancer (PCa) has a markedly inflammatory component, and patients frequently are elderly individuals who exhibit weight-related disorders, being obesity the most prevalent condition. Therefore, inflammation, and specifically, inflammasome complexes, could be crucial players in the interplay between PCa and metabolic disorders. In this review, we will: 1) discuss the potential role of each inflammasome component (sensor, molecular adaptor, and targets) in PCa pathophysiology, placing special emphasis on IL-1β/NF-kB pathway and ROS and hypoxia influence; 2) explore the association between inflammasomes and obesity, and how these molecular complexes could act as the cornerstone between the obesity and PCa; and, 3) compile current clinical trials regarding inflammasome targeting, providing some insights about their p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansProstatic NeoplasmsObesityInflammationSignal TransductionAgedMaleInflammasomesNLR Family, Pyrin Domain-Containing 3 Protein

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research